Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Asset Writedowns and Impairment (2019 - 2025)

Pulmonx (LUNG) has disclosed Asset Writedowns and Impairment for 7 consecutive years, with $72000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Asset Writedowns and Impairment rose 129.51% to $72000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $11000.0, a 99.29% decrease, with the full-year FY2024 number at $75000.0, up 227.12% from a year prior.
  • Asset Writedowns and Impairment was $72000.0 for Q3 2025 at Pulmonx, up from -$50000.0 in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $1.7 million in Q2 2024 to a low of -$454000.0 in Q2 2021.
  • A 5-year average of $170631.6 and a median of $46000.0 in 2022 define the central range for Asset Writedowns and Impairment.
  • Biggest YoY gain for Asset Writedowns and Impairment was 720.44% in 2024; the steepest drop was 24500.0% in 2024.
  • Pulmonx's Asset Writedowns and Impairment stood at $214000.0 in 2021, then fell by 20.56% to $170000.0 in 2022, then crashed by 134.71% to -$59000.0 in 2023, then soared by 159.32% to $35000.0 in 2024, then surged by 105.71% to $72000.0 in 2025.
  • Per Business Quant, the three most recent readings for LUNG's Asset Writedowns and Impairment are $72000.0 (Q3 2025), -$50000.0 (Q2 2025), and -$46000.0 (Q1 2025).